Hudson Technologies Enters Into Licensing Agreement With Chemours
06 mai 2024 08h30 HE
|
Hudson Technologies
WOODCLIFF LAKE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Hudson Technologies, Inc. (NASDAQ: HDSN) a leading provider of innovative and sustainable refrigerant products and services to the Heating,...
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
01 mai 2024 09h00 HE
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
01 mai 2024 06h25 HE
|
G1 Therapeutics
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
Copenhagen Infrastructure Partners secures two offshore wind feasibility licences in Australia and launches new platform company
01 mai 2024 04h00 HE
|
Copenhagen Infrastructure Partners
CIP secures two offshore wind feasibility licences in Australia and launches new platform company
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
30 avr. 2024 09h01 HE
|
ARS Pharmaceuticals, Inc.
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat...
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
29 avr. 2024 09h45 HE
|
Elevai Labs Inc.
Elevai Labs Releases Global Distribution Partnership Overview: Contracts Secure $11.5M Top Line Revenue Boost
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
26 avr. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
24 avr. 2024 07h00 HE
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Adeia Enters into Multi-year IP License Renewal with Altimedia
23 avr. 2024 08h30 HE
|
Adeia Inc.
SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), a company known for its groundbreaking innovations in entertainment experiences, has announced today that Altimedia, a...
Adeia, 미디어 플랫폼 기업인 Altimedia와 IP 라이선스 계약 다년 연장 합의
23 avr. 2024 08h30 HE
|
Adeia Inc.
미국 캘리포니아주 산호세, April 23, 2024 (GLOBE NEWSWIRE) -- 엔터테인먼트 경험의 새로운 혁신을 제시하는 Adeia Inc. (아데이아) (나스닥: ADEA)는 첨단 미디어 서비스 관리 솔루션 기업인 Altimedia (알티미디어)가 Adeia의 미디어 부문 지적재산권(IP) 포트폴리오에 대한 다년 간의 라이선스 계약을...